Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
RecruitingPhase 2
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Adults, 18 years of age or older on the day of signing the informed consent. 2. Thermal Burns not exceeding a total body surface area (TBSA) OF 25%, with at least one partial thickness burn of 0.5% TBSA or greater. If full thickness burn(s) are present at screening, the total full thickness burn area shall not exceed 10% TBSA. Note: TBSA excludes areas of superficial (first degree) burns. 3. Able and willing to give informed consent and comply with study procedures. Exclusion Criteria: 1. Any burn that at screening is: 1. infected. 2. circumferential or deemed, in the judgment of the investigator, at high risk for developing compartment syndrome. 3. partial thickness that is likely, in the judgment of the Investigator, to require grafting within 72 hours, or other non-protocol intervention. 2. Severe inhalation injury or other significant non-burn trauma.
About the study
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
What is being tested
- Investigational Drug, MW-III (drug)
- Silvadene® Cream 1% [Silver Sulfadiazine] (drug)
Sponsor: Skingenix, Inc. · Participants: 60 · Started: Mar 11, 2022
Contact the study team
- Vicki Christodoulou, MS, JD · Phone: 909-587-1650
- Eric Wang, MD · Phone: 909-587-1650
Official record on ClinicalTrials.gov — NCT01297400
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.